SAA1 as a CSF biomarker for neurosarcoidosis
Research type
Research Study
Full title
An assessment of serum amyloid A1 (SAA1) as a cerebrospinal fluid (CSF) biomarker for the identification of neurological involvement by Sarcoidosis and the differentiation of it from other inflammatory and neoplastic neurological diseases.
IRAS ID
204479
Contact name
Desmond Kidd
Contact email
Sponsor organisation
Royal Free London NHS Trust research and development department
Duration of Study in the UK
1 years, 6 months, 1 days
Research summary
Neurological involvement in sarcoidosis is difficult to identify particularly if no evidence for systemic sarcoidosis exists. These difficulties often result in misdiagnosis, delays in starting the correct treatment and even death. In an attempt to identify a more specific biomarker for the condition we propose a blood and cerbrospinal fluid (CSF) study of the acute phase protein serum amyloid A1 (SAA1) in patients with two forms of neurosarcoidosis and compare the results with a similar inflammatory condition and an non-inflammatory control group; all patients will be undergoing diagnostic procedures on separate clinical grounds and they are merely providing small extra samples in order to participate in the research.
REC name
South West - Frenchay Research Ethics Committee
REC reference
16/SW/0344
Date of REC Opinion
26 Jan 2017
REC opinion
Further Information Favourable Opinion